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Surgical management of hepatic metastases from gastric 
cancer is becoming one of the hot topics in gastric oncology. 
This is matter of satisfaction for the Italian Research Group on 
Gastric Cancer, who actively explored this particular subject. 
On the basis of our data and those from the literature, in a 
recent editorial we sponsored a “μετάνοια” (change of mind) 
that could lead to include surgery among the therapeutic 
options for a subgroup of metastatic gastric cancer patients (1).
We note that review articles follow each other with 
increasing frequency and almost parallel the number of 
research article but, fortunately, we also observe that the 
number of cases begins to rise. In fact, in 2010 Kerkar 
and colleagues (2) reviewed 436 patients collected from 
19 surgical series published over a 20-year time-span, in 
2014 Fitzgerald and colleagues (3) collected 481 cases 
published in the period 1990 to 2013, but the last review 
and meta-analysis, published on line in the spring of 
2016 (4), considered 991 patients who underwent liver 
resection for hepatic metastases from gastric cancer, 
recruited from 1990 to 2015. It really seems that seeds 
planted by a handful of Pioneers begin to grow and surgery, 
at least in referring centres, begins to be considered as 
one of the possible therapeutic options for these patients. 
Furthermore, the fact that a group of preeminent scientists 
and surgeons dedicates to this topic a full meta-analysis 
suggests that the route we explored may be correct.
The work by Markar and colleagues we were asked to 
comment shows some points of unequivocal agreement 
among the different authors that published in this domain, 
resumed as follows:
(I) Surgical indications are well established: liver only 
metastatic disease, preservation of postoperative 
liver function and surgical resection aimed to full 
control of hepatic and gastric disease (R0);
(II) In the above conditions surgery suffers very 
low mortality (median 0%, range, 0–30%) and 
morbidity rates typical of all major surgical 
procedures (median 24%, range, 0–48%);
(III) Pooled 1-, 3-, and 5-year survival were 68%, 31% 
and 27%, respectively, with a median survival of 
21 months (range, 9–52 months);
(IV) Eastern patients display better survival performances 
than their Western counterparts: at the considered 
time-point survival was 79% vs. 59%, 34% vs. 24.5% 
and 27.3% vs. 16.5%. Furthermore, the meta-analysis 
performed on comparative studies showed that:
(i) Surgical resection of hepatic metastases is 
associated to improved survival if compared 
to no surgical resection (HR =0.50; 95% CI: 
0.41–0.61; P<0.001);
(ii) Patients with solitary hepatic metastasis have 
better 5-year survival than those affected by 
multiple metastases who were operated on 
(OR =0.31; 95% CI: 0.13–0.76; P=0.011);
(iii) There is no difference in 5-year survival after 
resection of synchronous and metachronous 
metastases (OR =1.28; 95% CI: 0.46–3.57, 
P=0.631).
In extreme synthesis, the meta-analysis we are commenting 
gives official approval to the clinical experiences that 
originated the literature on this particular topic: surgery 
has a role in the management of a well defined subset of 
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metastatic gastric cancer.
We would like to add another statement to those listed 
above. It is self-explaining and immediate: multi-disciplinary 
approach offers the best results and adjuvant chemotherapy 
is a major prognostic factor in this subgroup of patients (5). 
To these editorialists, however, some critical points raised 
by the review merit special discussion.
The first and the one with greatest impact in every-day 
clinical practice is the selection of candidates to curative 
surgery. At present the curve that describes survival after 
surgery suffers a step drop during the first year, suggesting 
that some abusive procedures are performed: mortality is 
around 40% after 6 months and reaches 70–80% 1 year 
after surgery.
Some indications arise from six papers that (6-11) 
considered cohorts of patients as observed in every-day 
clinical practice and not upon super-selected populations 
submitted to surgical treatment. 
In the different settings of the disease, synchronous and 
metachronous presentation, simple clinical variables may be 
employed to select the best candidates for curative surgery 
(7,8,11) and those to be excluded from hepatic resection. In 
the synchronous setting (7) gastric cancer T>2 and scattered 
bilobar metastases (H3) are negative prognostic factors: 
median and 5-year survival was respectively 23 months 
and 27% for the 10% of cases which did not display the 
two risk factors, while patients affected by T≥3 gastric 
cancer and H3 metastases (30% of cases) displayed a 
median survival of 6 months and did not survive more than 
16 months. Accordingly, in the metachronous setting (11) 
the variable T4, N+ and G3 showed a negative prognostic 
role. Patients not presenting these variables (7%) had a 
5-year survival rate of 40%, those affected by two or three 
negative prognostic factors (48%) had a median survival 
of 4±3 months. Upon these bases, it is possible to select 
the best candidates for curative resection, those for whom 
an aggressive treatment should be mandatory, from those 
who will not benefit from hepatectomy. All together, they 
represent 40–55% of cases. In the middle one finds the 
huge group of cases presenting one risk factor. They do not 
display an astonishing survival performance (median survival 
is around 8–9 months). Yet among these it is possible to 
find long-term survivors. We think that in these cases the 
therapeutic decision should be discussed on a case by case 
basis, considering that a major prognostic factor emerging 
from the literature is represented by the possibility to 
achieve a curative resection.
The second point we want to discuss concerns the 
different prognostic factors in the subgroup of patients 
submitted to hepatectomy. Two of them have special 
importance. Gastric cancer progression through the 
serosa (T4) is a negative prognostic determinant that must 
always be considered, as it opens the door of the peritoneal 
cavity (5,12-14). Beside this, we would like to insist here 
that the completeness of tumor bulk removal is the key-
point of the therapeutic strategy. The expansion of the 
experience and the most recent series focusing on surgical 
subgroups, indicate this point precisely. In a recent review 
of our cases (5), we were surprised by the absence, once 
excluded the factor T of the gastric primary, of other gastric 
cancer or metastasis-related prognostic variables emerging 
from our data. Indeed, this enhances the surgeon’s role in 
the management of these cases. 
In the synchronous setting R0 resection must be 
achieved both on the hepatic metastases and on the gastric 
primary, thus gastrectomy must be routinely associated to 
D≥2 lymphectomy.
In our experience, once R0 resection can be achieved, 
the extent of hepatic involvement no longer influences the 
prognosis. This finding is in contrast with data from some 
of the most numerous cohorts published (6,8,10,15,16) 
but merits full attention. From a speculative point of view, 
this enforces the idea that hepatic metastases may still be 
included in the concept of regional disease, which may 
benefit from regional surgery. This concept is well validated 
for metastases from colorectal cancer, but it is absolutely 
new for metastases from gastric cancer.
The third point concerns the prognostic role displayed 
by the timing of metastatic disease.
Clinicians consider the metachronous presentation as 
more favorable. The conclusion of the commented meta-
analysis seems to contradict this certitude. It must be noted, 
however, that they only considered the 5-year survival 
and not the entire survival curve. Patients submitted to 
hepatectomy for metachronous metastases benefit of a 
better selection and display better survival performance in 
the short and medium term; at 5 years, however, survival 
curves tend to approximate each-other (5).
Concluding this editorial we’d like to comment the 
observation by Markar and co-authors concerning the 
limits of literature as far as the performance status and 
co-morbidity of studied patients are considered. We are 
confident that in this phase the majority of surgeons 
reserved their attention to the best patients, those fit for 
surgery and with the more favourable hepatic involvement. 
We fully appreciate the scientific biases linked to these limits 
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but also the results emerging from the simple, common-
sense oriented clinical practice. These results encourage 
the surgical treatment of these cases, at least in the best 
conditions. The biologic impact of this kind surgery is also 
unknown, but we noted in our outpatient activity that the 
postoperative period is easy, that patients perform well and 
are generally satisfied of the treatment they received. These 
are all the reasons that encourage our activity in promoting 
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